These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9581697

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.
    Int J Cancer; 2000 Sep 01; 87(5):741-9. PubMed ID: 10925370
    [Abstract] [Full Text] [Related]

  • 3. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN.
    J Gastroenterol Hepatol; 2005 Oct 01; 20(10):1553-9. PubMed ID: 16174073
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC.
    Clin Interv Aging; 2016 Oct 01; 11():1035-41. PubMed ID: 27536084
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2007 Oct 01; 50(1):16-23. PubMed ID: 17164553
    [Abstract] [Full Text] [Related]

  • 8. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, Okita K.
    J Viral Hepat; 2000 Sep 01; 7(5):343-51. PubMed ID: 10971822
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, Shingai Y, Konishi T, Yamashita S, Uchida K, Mori K, Hanada H, Kodama T, Nukui K, Okita K.
    J Viral Hepat; 2002 Sep 01; 9(5):370-6. PubMed ID: 12225332
    [Abstract] [Full Text] [Related]

  • 13. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T, Osaka Liver Forum.
    Clin Gastroenterol Hepatol; 2014 Jul 01; 12(7):1186-95. PubMed ID: 24321207
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2004 Jul 01; 47(6):355-61. PubMed ID: 15564748
    [Abstract] [Full Text] [Related]

  • 16. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
    Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.
    Ann Intern Med; 1998 Jul 15; 129(2):94-9. PubMed ID: 9669992
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.
    Moriyama M, Matsumura H, Aoki H, Shimizu T, Nakai K, Saito T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y.
    Intervirology; 2003 Jul 15; 46(5):296-307. PubMed ID: 14555850
    [Abstract] [Full Text] [Related]

  • 18. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C, Poovorawan Y, Sura T, Theamboonlers A, Busagorn N, Kurathong S.
    Southeast Asian J Trop Med Public Health; 1998 Sep 15; 29(3):480-90. PubMed ID: 10437943
    [Abstract] [Full Text] [Related]

  • 19. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
    Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T.
    Ann Intern Med; 2007 May 01; 146(9):649-56. PubMed ID: 17470833
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.